Cambridge, United States
ProMIS™ Neurosciences, Inc., founded in 2015 and headquartered in Canada, is a pioneering entity within the Biotechnology and Health Care sectors. The company is committed to developing next-generation, disease-modifying treatments specifically targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy.
With its focus on the discovery and development of antibodies selective for toxic misfolded proteins, ProMIS leverages cutting-edge technology to address these neurodegenerative diseases. This strategic approach positions them effectively within the Health and Wellness industry, catering to an urgent and unmet medical need.
The company recently secured a significant $122.70M Post-IPO Equity investment on July 26, 2024, with participation from leading investors such as Ally Bridge Group, Great Point Partners, Sphera Global Healthcare Fund, and Armistice Capital. This robust backing underscores investor confidence and positions ProMIS for sustainable growth and further innovation in its target fields.
-logo.jpg "Kineta (Reverse Merger With Yumanity Therapeutics)"){kind=logo}
AltPep